In a major advance for dermatological healthcare, Chinese regulatory authorities have approved an innovative oral psoriasis medication jointly developed by Johnson & Johnson and Protagonist Therapeutics.

The landmark decision provides a convenient, needle-free therapeutic alternative for patients struggling with moderate-to-severe forms of the chronic autoimmune skin disorder across China.

The approval represents a significant commercial milestone for both pharmaceutical partners, significantly expanding their clinical footprint in the rapidly growing Asian medical market.